Travel medicine and infectious disease
-
Travel Med Infect Dis · Mar 2020
Observational StudyClinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study.
We need an effective treatment to cure COVID-19 patients and to decrease virus carriage duration. ⋯ We believe there is urgency to evaluate the effectiveness of this potentially-life saving therapeutic strategy at a larger scale, both to treat and cure patients at an early stage before irreversible severe respiratory complications take hold and to decrease duration of carriage and avoid the spread of the disease. Furthermore, the cost of treatment is negligible.
-
Travel Med Infect Dis · Mar 2020
Testing the repatriated for SARS-Cov2: Should laboratory-based quarantine replace traditional quarantine?
An ongoing epidemic of respiratory diseases caused by a novel coronavirus (COVID 2019, SARS-CoV2) started in Wuhan, Hubei, in China at the end of December 2019. The French government decided to repatriate the 337 French nationals living in Wuhan and place them in quarantine in their home country. We decided to test them all for SARS-Cov2 twice in order to reduce anxiety among the population and decision-makers. ⋯ Optimising our procedures reduces anxiety and reassures the population and decision makers.